Drug Profile

TGM 010

Alternative Names: TGM-010

Latest Information Update: 16 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GenrAb
Class Antibodies; Neuroprotectants
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Neurodegenerative disorders

Most Recent Events

22 Apr 2025 Preclinical trials in Neurodegenerative disorders in USA (Parenteral), before April 2025
22 Apr 2025 Pharmacodynamics data from preclinical trials in Neurodegenerative disorders released by GenrAb, before April 2025 (GenrAb pipeline, April 2025)
22 Apr 2025 GenrAb plans clinical studies for TGM 010 in 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com